Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis

References

• Centers for Disease Control and Prevention (CDC). Isolation of avian influenza A(H5N1) viruses from humans–Hong Kong, May-December 1997. MMWR Morb Mortal Wkly Rep. 1997;46(50):1204–07.
   PubMedGoogle Scholar
• Chan PKS. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis. 2002;34:S58–64. doi:10.1086/338820.
   PubMed Web of Science ®Google Scholar
• Smith GJD, Wang J, Fan XH, Qin K, Zhang JX, Vijaykrishna D, Cheung CL, Rayner MJ, J Peiris JSM, Chen H, et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A. 2006;103(45):16936–41. doi:10.1073/pnas.0608157103.
   PubMed Web of Science ®Google Scholar
• Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Hatta Y, Gao P, Ozawa M, Le QM, Kawaoka Y. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol. 2011;85(10):5202–07. doi:10.1128/JVI.00239-11.
   PubMed Web of Science ®Google Scholar
• WHO. Update: WHO-confirmed human cases of avian Influenza A (H5N1) infection, november 2003-May 2008. Wkly Epidemiol Rec. 2008;83(46):415–20.
   PubMedGoogle Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354(13):1343–51. doi:10.1056/NEJMoa055778.
   PubMed Web of Science ®Google Scholar
• Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JPA, Villari P. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis. 2009;9(8):482–92. doi:10.1016/S1473-3099(09)70153-7.
   PubMed Web of Science ®Google Scholar
• Guo Q, Liu Z, Gao J, Zhou J, Hu W, Cun Y, Li W, Liao G. Immunogenicity and safety of pandemic Influenza H5N1 vaccines in healthy adults through meta-analysis. Cell Physiol Biochem. 2016;40(5):921–32. doi:10.1159/000453150.
   PubMedGoogle Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177–84. doi:10.1159/000069172.
   PubMed Web of Science ®Google Scholar
• Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health. 1987;77(6):712–16. doi:10.2105/ajph.77.6.712.
   PubMed Web of Science ®Google Scholar
• Chan TC, Hung IF, Cheng VC, Luk JK, Chu LW, Chan FH. Is nursing home residence an independent predictor of recurrent hospitalization in older adults? J Am Med Dir Assoc. 2013;14(9):706–07. doi:10.1016/j.jamda.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama. 2003;28(2):179–86. doi:10.1001/jama.289.2.179.
   Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. Jama. 2004;292(11):1333–40. doi:10.1001/jama.292.11.1333.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7(10):658–66. doi:10.1016/S1473-3099(07)70236-0.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P, Morelli P, Morelli P, Comino I, Calderisi S, et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine. 2002;20(Suppl 5):B50–4. doi:10.1016/s0264-410x(02)00507-8.
   PubMedGoogle Scholar
• Loperto I, Andrea S, Antonio N, Triassi M. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. Hum Vaccin Immunother. 2019;15(5):1035–47. doi:10.1080/21645515.2019.1578597.
   PubMed Web of Science ®Google Scholar
• Schaffner W, Chen WH, Hopkins RH, Neuzil K. Effective immunization of older adults against seasonal influenza. Am J Med. 2018;131(8):865–73. doi:10.1016/j.amjmed.2018.02.019.
   PubMed Web of Science ®Google Scholar
• Rumke HC, Richardus JH, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis. 2013;13:348. doi:10.1186/1471-2334-13-348.
   PubMed Web of Science ®Google Scholar
• Schaffner W, van Buynder P, McNeil S, Osterhaus ADEM. Seasonal influenza immunisation: strategies for older adults. Int J Clin Pract. 2018;72:e13249. doi:10.1111/ijcp.13249.
   PubMed Web of Science ®Google Scholar
• Weinberger B. Adjuvant strategies to improve vaccination of the elderly population. Curr Opin Pharmacol. 2018;41:34–41. doi:10.1016/j.coph.2018.03.014.
   PubMed Web of Science ®Google Scholar
• Cancro MP, Hao Y, Scholz JL, Riley RL, Frasca D, Dunn-Walters KD, Blomberg BB. B cells and aging: molecules and mechanisms. Trends Immunol. 2009;30(7):313–18. doi:10.1016/j.it.2009.04.005.
   PubMed Web of Science ®Google Scholar
• Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, et al. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018;36(10):1272–78. doi:10.1016/j.vaccine.2018.01.045.
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44. doi:10.1016/S1473-3099(11)70295-X.
   PubMed Web of Science ®Google Scholar
• Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z, Luke C, Treanor J, Subbarao K. Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9). J Infect Dis. 2016;213(6):922–29. doi:10.1093/infdis/jiv526.
   PubMed Web of Science ®Google Scholar
• Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009;27(37):5091–95. doi:10.1016/j.vaccine.2009.06.057.
   PubMed Web of Science ®Google Scholar
• Gou X, Xiaoxue W, Shi Y, Zhang K, Huang J. A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza. Hum Vaccin Immunother. 2020;16(2):286–94. doi:10.1080/21645515.2019.1649551.
   PubMed Web of Science ®Google Scholar
• Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision).Committee for guidance for human medicinal products (CHMP). EMEA/CPMP/VEG/4717/2003- Rev. 1; 2008.
   Google Scholar
• Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER); 2007.
   Google Scholar
• Leroux-Roels I, Van der Wielen M, Kafeja F, Vandermeulen C, Lazarus R, Snape MD, John T, Carre C, Nougarede N, Pepin S, et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine. 2009;27(49):6918–25. doi:10.1016/j.vaccine.2009.08.110.
   PubMed Web of Science ®Google Scholar
• Czajka H, Unal S, Ulusoy S, Usluer G, Strus A, Sennaroglu E, Guzik J, Iskit AT, Dargiewicz A, Musial D, et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg. 2012;53(3):136–42.
   PubMedGoogle Scholar
• Vesikari T, Forsten A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, Sonnenburg FV. Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine. 2012;30(7):1388–96. doi:10.1016/j.vaccine.2011.12.009.
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Giovanni PD, Sticchi L, Gentile C, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384. doi:10.1371/journal.pone.0004384.
   PubMed Web of Science ®Google Scholar
• Bihari I, Panczel G, Kovacs J, Beygo J, Fragapane E. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. Clin Vaccine Immunol. 2012;19(12):1943–48. doi:10.1128/CVI.00373-12.
   PubMed Web of Science ®Google Scholar
• MVM VDV, Aichinger G, Pollabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine. 2012;30(43):6127–35. doi:10.1016/j.vaccine.2012.07.077.
   PubMed Web of Science ®Google Scholar
• Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Dramé M, Roman F, Gillard P. Immunogenicity profile of a 3.75-mug hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis. 2011;203(8):1054–62. doi:10.1093/infdis/jiq174.
   PubMed Web of Science ®Google Scholar
• Vajo Z, Wood J, Kosa L, Szilvasy I, Paragh G, Pauliny Z, Bartha K, Visontay I, Kis A, Jankovics I. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J Virol. 2010;84(3):1237–42. doi:10.1128/JVI.01894-09.
   PubMed Web of Science ®Google Scholar
• S E F, Shakib S, Chanthavanich P, Richmond P, Smith T, Tantawichien T, Kittel C, Jaehnig P, ZSafety M, Kanesa-Thasan N, et al. Safety and immunogenicity of MF59-adjuvanted cell culture–derived A/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly. Open Forum Infect Dis. 2019;6(4):ofz107. doi:10.1093/ofid/ofz107.
   PubMed Web of Science ®Google Scholar
• Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavaldà J, Moreno A, Torre-Cisneros J, Montejo JM, Fortun J, Muñoz P, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64(7):829–38. doi:10.1093/cid/ciw855.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, et al. Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine. 2018;29:146–54. doi:10.1016/j.ebiom.2018.02.011.
   PubMed Web of Science ®Google Scholar
• Ko EJ, Kang SM. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother. 2018;14(12):3041–45. doi:10.1080/21645515.2018.1495301.
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi:10.1016/j.smim.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Gemmill I, Young K. Summary of the NACI literature review on the comparative effectiveness of subunit and split virus inactivated influenza vaccines in older adults. Can Commun Dis Rep. 2019;45(6):129–33. doi:10.14745/ccdr.v44i06a02.
   Google Scholar
• Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HML, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, et al. Ehrlich. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine. 2012;30(2):329–35. doi:10.1016/j.vaccine.2011.10.088.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, Goldenthal KL, Kohberger R, Dunkle LM. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE + GLA) adjuvant. Vaccine. 2013;31(48):5760–65. doi:10.1016/j.vaccine.2013.08.064.
   PubMed Web of Science ®Google Scholar
• Dermont MA, Elmer T. Influenza syndromic surveillance and vaccine efficacy in the UK armed forces, 2017-2018. J R Army Med Corps. 2019;165(6):395–99. doi:10.1136/jramc-2018-001067.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Frey SE, Graham IL, Edwin L, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. Jama. 2014;312(14):1420–28. doi:10.1001/jama.2014.12609.
   PubMed Web of Science ®Google Scholar
• Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A (H5N1) virus vaccine administered with or without AS03 adjuvant. Open Forum Infect Dis. 2014;1(3):ofu091. doi:10.1093/ofid/ofu091.
   PubMedGoogle Scholar
• Wu UI, Hsieh SM, Lee WS, Wang NC, Kung HC, Ou TY, Chen FL, Lin TY, Chen YC, Chang SH. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial. Vaccine. 2017;35(33):4099–104. doi:10.1016/j.vaccine.2017.06.044.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Jama. 2014;312(14):1409–19. doi:10.1001/jama.2014.12854.
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008;2(6):243–49. doi:10.1111/j.1750-2659.2008.00059.x.
   PubMed Web of Science ®Google Scholar
• Diallo A, Victor JC, Feser J, Ortiz JR, Kanesa-Thasan N, Ndiaye M, Diarra B, Cheikh S, Diene D, Ndiaye T, et al. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naive children in a randomized clinical trial in rural Senegal. Vaccine. 2018;36(43):6424–32. doi:10.1016/j.vaccine.2018.08.032.
   PubMed Web of Science ®Google Scholar
• Huang WT, Huang YS, Hsu CY, Chen HC, Lee HC, Lin HC, Hsieh CF, Wu MN, Yang CH. Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan. Sleep Med. 2018;66:276–81. doi:10.1016/j.sleep.2018.10.036.
   PubMed Web of Science ®Google Scholar
• Basavaraj VH, Sampath G, Hegde NR, Mohan VK, Ella KM. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in phase I single centre and phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine. 2014;32(35):4592–97. doi:10.1016/j.vaccine.2014.05.039.
   PubMed Web of Science ®Google Scholar
• Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009;27(47):6642–48. doi:10.1016/j.vaccine.2009.03.015.
   PubMed Web of Science ®Google Scholar
• Yin DP, Zhu BP, Wang HQ, Cao L, Wu WD, Jiang KY, Xia W, Guo Zhang M, Zheng JS, Cao LS, et al. Effect of aluminum hydroxide adjuvant on the immunogenicity of the 2009 pandemic influenza A/H1N1 vaccine: multi-level modeling of data with repeated measures. Biomed Environ Sci. 2011;24(6):624–29. doi:10.3967/0895-3988.2011.06.006.
   PubMed Web of Science ®Google Scholar